

Tatsunori Kiriu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/898297/publications.pdf>

Version: 2024-02-01

14
papers

308
citations

1040056

9
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

695
citing authors

#	ARTICLE	IF	CITATIONS
1	<p><p>>Caspase Recruitment Domain-Containing Protein 9 Expression is a Novel Prognostic Factor for Lung Adenocarcinoma</p></p>. OncoTargets and Therapy, 2020, Volume 13, 9005-9013.	2.0	3
2	Pulmonary large cell neuroendocrine carcinoma with adrenal oligorecurrence successfully treated by adrenalectomy. Respiriology Case Reports, 2020, 8, e00618.	0.6	0
3	<p><p>>Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC</p></p>. Cancer Management and Research, 2020, Volume 12, 777-782.	1.9	4
4	<p><p>>A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy</p></p>. Cancer Management and Research, 2019, Volume 11, 7135-7140.	1.9	5
5	<p><p>>Synergistic interaction of gemcitabine and paclitaxel by modulating acetylation and polymerization of tubulin in non-small cell lung cancer cell lines</p></p>. Cancer Management and Research, 2019, Volume 11, 3669-3679.	1.9	13
6	<p><p><Novel cancer therapy targeting microbiome</p>. OncoTargets and Therapy, 2019, Volume 12, 3619-3624.	2.0	28
7	Crucial Role of Extracellular Vesicles in Bronchial Asthma. International Journal of Molecular Sciences, 2019, 20, 2589.	4.1	32
8	<p><p>>Pseudo-Progression and the Neutrophil-to-Lymphocyte Ratio in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Case<sup>e</sup>-Control Study</p></p>. OncoTargets and Therapy, 2019, Volume 12, 10559-10568.	2.0	15
9	Prognostic Value of Red Blood Cell Distribution Width in Non-small Cell Lung Cancer Treated With Anti-programmed Cell Death-1 Antibody. In Vivo, 2019, 33, 213-220.	1.3	15
10	Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer. Anticancer Research, 2019, 39, 815-825.	1.1	73
11	Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease. Internal Medicine, 2018, 57, 91-95.	0.7	24
12	The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS ONE, 2018, 13, e0193018.	2.5	64
13	Glucose metabolism<sup>e</sup>-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor<sup>e</sup>-induced drug<sup>e</sup>-tolerant persisters. Cancer Science, 2017, 108, 1368-1377.	3.9	28
14	Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study. Respiratory Investigation, 2016, 54, 334-340.	1.8	4